HER2CLIMB-05: the role of tucatinib in HER2-positive metastatic breast cancer

Intervista a Erika Hamilton By 10 Dicembre 2025No Comments
Dai congressi

Adding tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS) 2025. We interviewed Erika Hamilton (Director of Breast Cancer Research – Sarah Cannon Research Institute SCRI, Nashville) during the congress.